2.14 USD
-0.06 (-2.73%)
Last: Jan 30, 2026, 11:29 AM
We assign a fundamental rating of 3 out of 10 to STIM. STIM was compared to 184 industry peers in the Health Care Equipment & Supplies industry. STIM has a bad profitability rating. Also its financial health evaluation is rather negative. STIM is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
- STIM had negative earnings in the past year.
- In the past year STIM has reported a negative cash flow from operations.
- STIM had negative earnings in each of the past 5 years.
- STIM had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- With a Return On Assets value of -30.59%, STIM perfoms like the industry average, outperforming 43.48% of the companies in the same industry.
- Looking at the Return On Equity, with a value of -162.68%, STIM is doing worse than 67.93% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -30.59% | ||
| ROE | -162.68% | ||
| ROIC | N/A |
ROA(3y)-29.62%
ROA(5y)-29.17%
ROE(3y)-103.71%
ROE(5y)-91.08%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- STIM has a Gross Margin of 50.43%. This is comparable to the rest of the industry: STIM outperforms 45.65% of its industry peers.
- In the last couple of years the Gross Margin of STIM has remained more or less at the same level.
- STIM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 50.43% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.88%
GM growth 5Y-0.84%
2. Health
2.1 Basic Checks
- STIM does not have a ROIC to compare to the WACC, probably because it is not profitable.
- The number of shares outstanding for STIM has been increased compared to 1 year ago.
- Compared to 5 years ago, STIM has more shares outstanding
- The debt/assets ratio for STIM has been reduced compared to a year ago.
2.2 Solvency
- STIM has an Altman-Z score of -3.16. This is a bad value and indicates that STIM is not financially healthy and even has some risk of bankruptcy.
- STIM has a worse Altman-Z score (-3.16) than 64.67% of its industry peers.
- A Debt/Equity ratio of 2.40 is on the high side and indicates that STIM has dependencies on debt financing.
- Looking at the Debt to Equity ratio, with a value of 2.40, STIM is doing worse than 83.70% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.4 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -3.16 |
ROIC/WACCN/A
WACC11.04%
2.3 Liquidity
- A Current Ratio of 2.24 indicates that STIM has no problem at all paying its short term obligations.
- The Current ratio of STIM (2.24) is comparable to the rest of the industry.
- STIM has a Quick Ratio of 2.09. This indicates that STIM is financially healthy and has no problem in meeting its short term obligations.
- STIM has a Quick ratio of 2.09. This is comparable to the rest of the industry: STIM outperforms 56.52% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.24 | ||
| Quick Ratio | 2.09 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 33.33% over the past year.
- The Revenue has grown by 78.62% in the past year. This is a very strong growth!
- STIM shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 3.63% yearly.
EPS 1Y (TTM)33.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70.45%
Revenue 1Y (TTM)78.62%
Revenue growth 3Y10.63%
Revenue growth 5Y3.63%
Sales Q2Q%101.28%
3.2 Future
- The Earnings Per Share is expected to grow by 18.70% on average over the next years. This is quite good.
- STIM is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 26.89% yearly.
EPS Next Y55.83%
EPS Next 2Y28.74%
EPS Next 3Y20.66%
EPS Next 5Y18.7%
Revenue Next Year105.05%
Revenue Next 2Y50.78%
Revenue Next 3Y36.66%
Revenue Next 5Y26.89%
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for STIM. In the last year negative earnings were reported.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for STIM. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- STIM's earnings are expected to grow with 20.66% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.74%
EPS Next 3Y20.66%
5. Dividend
5.1 Amount
- STIM does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NEURONETICS INC / STIM FAQ
What is the ChartMill fundamental rating of NEURONETICS INC (STIM) stock?
ChartMill assigns a fundamental rating of 3 / 10 to STIM.
What is the valuation status of NEURONETICS INC (STIM) stock?
ChartMill assigns a valuation rating of 1 / 10 to NEURONETICS INC (STIM). This can be considered as Overvalued.
Can you provide the profitability details for NEURONETICS INC?
NEURONETICS INC (STIM) has a profitability rating of 1 / 10.
What is the earnings growth outlook for NEURONETICS INC?
The Earnings per Share (EPS) of NEURONETICS INC (STIM) is expected to grow by 55.83% in the next year.